AAP
GMAB icon

Ardsley Advisory Partners’s Genmab GMAB Stock Holding History

Ardsley Advisory Partners’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-7,500
Closed -$254K – 162
2020
Q2 		$254K Buy
+7,500
New +$204K 0.05% 113

Other funds holding GMAB

Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ardsley Advisory Partners's GMAB Position: Q3 2020 in Review

Ardsley Advisory Partners sold out of Genmab (GMAB) in Q3 2020, closing a stake of 7,500 shares — an estimated $254K sold.

Ardsley Advisory Partners first reported a position in GMAB in Q2 2020 and held it in 1 quarter. The position peaked at $254K in Q2 2020. 198 funds tracked by Wall St. Rank hold GMAB as of Q3 2020.

  • Ardsley Advisory Partners reported no remaining Genmab position as of Q3 2020 after selling out during the quarter.
  • Ardsley Advisory Partners sold 7,500 Genmab shares in Q3 2020, an estimated $254K.
  • Ardsley Advisory Partners first reported a position in Genmab in Q2 2020 and held it in 1 quarter.
  • Ardsley Advisory Partners's Genmab position peaked at $254K in Q2 2020.
  • 198 funds tracked by Wall St. Rank held Genmab as of Q3 2020.

Based on Ardsley Advisory Partners's 13F filing for Q3 2020, filed 13 Nov 2020.